[go: up one dir, main page]

AU2001232267A1 - Remedies for hepatitis c - Google Patents

Remedies for hepatitis c

Info

Publication number
AU2001232267A1
AU2001232267A1 AU2001232267A AU3226701A AU2001232267A1 AU 2001232267 A1 AU2001232267 A1 AU 2001232267A1 AU 2001232267 A AU2001232267 A AU 2001232267A AU 3226701 A AU3226701 A AU 3226701A AU 2001232267 A1 AU2001232267 A1 AU 2001232267A1
Authority
AU
Australia
Prior art keywords
hepatitis
remedies
virus
present
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001232267A
Inventor
Seima Itami
Yoshiharu Matsuura
Tatsuo Miyamura
Makoto Seki
Tatsurou Shibui
Yoshihisa Yotsumoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
JAPAN AS REPRESENTED BY DIRECTOR GENERAL OF AGENCY OF NATIONAL INSTITUTE OF INFECTIOUS DESEASES
Tanabe Pharma Corp
Original Assignee
JP AGENCY OF NAT
Mitsubishi Tokyo Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by JP AGENCY OF NAT, Mitsubishi Tokyo Pharmaceuticals Inc filed Critical JP AGENCY OF NAT
Publication of AU2001232267A1 publication Critical patent/AU2001232267A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C07K16/118—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Steroid Compounds (AREA)

Abstract

The present invention provides a substance which inhibits the binding between E2/NS1 protein of hepatitis C virus and a cell infectious with hepatitis C virus, a cell expressing CD81, or CD81. The present invention can provide a novel medicament which has an anti-viral effects such as an inhibitory action against HCV infection.
AU2001232267A 2000-02-14 2001-02-13 Remedies for hepatitis c Abandoned AU2001232267A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000-34906 2000-02-14
JP2000034906 2000-02-14
PCT/JP2001/000967 WO2001058459A1 (en) 2000-02-14 2001-02-13 Remedies for hepatitis c

Publications (1)

Publication Number Publication Date
AU2001232267A1 true AU2001232267A1 (en) 2001-08-20

Family

ID=18559171

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001232267A Abandoned AU2001232267A1 (en) 2000-02-14 2001-02-13 Remedies for hepatitis c

Country Status (8)

Country Link
US (1) US7101551B2 (en)
EP (1) EP1256348B1 (en)
KR (1) KR20020091093A (en)
CN (1) CN100391469C (en)
AT (1) ATE555794T1 (en)
AU (1) AU2001232267A1 (en)
BR (1) BR0108499A (en)
WO (1) WO2001058459A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR047392A1 (en) 2002-10-22 2006-01-18 Wyeth Corp NEUTRALIZATION OF ANTIBODIES AGAINST GDF 8 AND ITS USE FOR SUCH PURPOSES
US20060275289A1 (en) * 2003-08-28 2006-12-07 Takamasa Watanabe Preventive or remedy for inflammatory bowel diseases containing anti-cd81 antibody as the active ingredient
US7750115B2 (en) * 2004-03-31 2010-07-06 Patent Technology Development, Inc. Epithelial cell growth promoter
KR101704809B1 (en) 2005-04-18 2017-02-08 암젠 리서치 (뮌헨) 게엠베하 Antibody neutralizers of human granulocyte macrophage colony stimulating factor
KR20110021832A (en) * 2008-05-02 2011-03-04 노파르티스 아게 Improved fibronectin-based binding molecules and uses thereof
ES2860453T3 (en) 2009-10-30 2021-10-05 Novartis Ag Universal libraries of type III fibronectin underside binding domain
CA2800734A1 (en) 2010-05-25 2011-12-01 Universite De Strasbourg Combination of anti-envelope antibodies and anti-receptor antibodies for the treatment and prevention of hcv infection
EP2650367A4 (en) * 2010-12-06 2015-07-08 Sumitomo Dainippon Pharma Co Ltd Human monoclonal antibody
WO2013024155A1 (en) 2011-08-17 2013-02-21 Inserm (Institut National De La Sante Et De La Recherche Medicale) Combinations of anti-hcv-entry factor antibodies and direct acting antivirals for the treatment and the prevention of hcv infection
WO2013024157A2 (en) 2011-08-17 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations of host targeting agents for the treatment and the prevention of hcv infection
WO2013024156A2 (en) 2011-08-17 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations of anti-hcv-entry factor antibodies and interferons for the treatment and the prevention of hcv infection
WO2013024158A1 (en) 2011-08-17 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations of protein kinase inhibitors and interferons or of protein kinase inhibitors and direct acting antivirals for the treatment and the prevention of hcv infection
WO2014033266A1 (en) 2012-08-31 2014-03-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-sr-bi antibodies for the inhibition of hepatitis c virus infection
EP2914289B1 (en) 2012-10-31 2019-05-22 Takeda GmbH Lyophilized formulation comprising gm-csf neutralizing compound
AR093297A1 (en) 2012-10-31 2015-05-27 Amgen Res Munich Gmbh LIQUID FORMULATION THAT INCLUDES A GM-CSF NEUTRALIZING COMPOUND
KR20220045064A (en) 2013-08-30 2022-04-12 다케다 야쿠힌 고교 가부시키가이샤 Antibodies neutralizing gm-csf for use in the treatment of rheumatoid arthritis or as analgesics
WO2015188141A2 (en) 2014-06-06 2015-12-10 Memorial Sloan-Kettering Cancer Ceneter Mesothelin-targeted chimeric antigen receptors and uses thereof
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
AU2019306628B2 (en) 2018-07-20 2024-11-14 Surface Oncology, LLC Anti-CD112R compositions and methods

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5574132A (en) * 1991-04-05 1996-11-12 Biochem Immunosystems Inc. Peptides and mixtures thereof for detecting antibodies to hepatitis C virus (HCV)
EP0697888B1 (en) * 1993-05-12 2003-09-17 Chiron Corporation Conserved motif of hepatitis c virus e2/ns1 region
CN1044384C (en) * 1994-08-25 1999-07-28 中国药品生物制品检定所 Establishment of Anti-HCV Antigen Monoclonal Antibody Cell Line and Its Monoclonal Antibody
CN1072482C (en) 1996-11-08 2001-10-10 山东医科大学 Low-molecular heparin liposome spray preparation and its preparation
PT1021534E (en) * 1997-10-06 2010-03-03 Novartis Vaccines & Diagnostic Hepatitis c receptor protein cd81
CN1325517C (en) 1998-07-21 2007-07-11 展马博联合股份有限公司 Anti-hepatitis C virus antibody and use thereof
JP2002528140A (en) * 1998-11-05 2002-09-03 ザ ボード オブ トラスティーズ オブ リーランド スタンフォード ジュニア ユニバーシティ Human PAN-HCV human monoclonal antibody
EP1293564A4 (en) 2000-06-08 2005-08-17 Mitsubishi Pharma Corp EXPRESSION VECTOR FOR SCREENING CELLS HAVING HIGH EXPRESSION OF RECOMBINANT PROTEIN, TRANSFORMING AT HIGH EXPRESSION OF RECOMBINANT PROTEIN, AND USE THEREOF

Also Published As

Publication number Publication date
BR0108499A (en) 2003-03-11
EP1256348A4 (en) 2005-07-27
KR20020091093A (en) 2002-12-05
EP1256348A1 (en) 2002-11-13
CN100391469C (en) 2008-06-04
WO2001058459A1 (en) 2001-08-16
CN1423561A (en) 2003-06-11
EP1256348B1 (en) 2012-05-02
US7101551B2 (en) 2006-09-05
US20030157132A1 (en) 2003-08-21
ATE555794T1 (en) 2012-05-15

Similar Documents

Publication Publication Date Title
AU2001232267A1 (en) Remedies for hepatitis c
WO2004011478A3 (en) Anti-viral 7-deaza d-nucleosides and uses thereof
WO2007001406A3 (en) Aryl-containing macrocyclic compounds
WO2001077091A3 (en) Ns5b hcv polymerase inhibitors
WO2006033995A3 (en) Thiazolidin-4-ones having anti-hepatitis b activity
WO2003053349A3 (en) Inhibitors of hepatitis c virus
WO2007084413A3 (en) Methods for treating hepatitis c
PT1169339E (en) ACTIVE MACROCYCLIC PEPTIDES AGAINST HEPATITIS C VIRUSES
WO2003093290A8 (en) Nucleoside derivatives for treating hepatitis c virus infection
GEP20104956B (en) Compounds for inhibiting hepatitis c viral replication and use thereof
WO2004060308A3 (en) Thiosemicarbazones as anti-virals and immunopotentiators
MXPA02012443A (en) 3 -PRODRUGS OF 2 -DEOXY-bgr;-L-NUCLEOSIDES.
DE50102597D1 (en) MEDICINE AGAINST VIRAL DISEASES
WO2003055896A3 (en) Anti-viral 7-deaza l-nucleosides
AU7602800A (en) Hepatitis c virus envelope two protein (e2) which lacks all or part of the hypervariable region one (hvr1), corresponding nucleic acids, chimeric viruses and uses thereof
WO2002062959A3 (en) Hepatitis b virus treatment
AU2002346686A1 (en) Compositions and method for treating hepatitis virus infection
ATE299709T1 (en) ANTI-VIRAL COMPOSITION CONTAINING A PALMARIA PALMATA EXTRACT
AU2002219881A1 (en) Methods and compositions for the treatment of human immunodeficiency virus infection
WO2003053332A3 (en) Composition and method for treating viral infection
AU2002322082A1 (en) Pharmaceutical composition for the treatment of viral infection
AU2003237088A1 (en) Compounds, compositions and methods for treating or preventing viral infections and associated diseases
WO2004071462A3 (en) Methods and compositions for treatment of viral infections based on tsg101-vps28 interaction
TR200201954T2 (en) Medicinal substances for viral diseases.
DE69726602D1 (en) Hepatitis b inhibitoren